Femasys Inc. (NASDAQ:FEMY) Short Interest Down 47.8% in December

Femasys Inc. (NASDAQ:FEMY) saw a significant decline in short interest in December. As of December 31st, there was short interest totalling 225,800 shares, a decline of 47.8% from the December 15th total of 432,800 shares. Currently, 1.1% of the company’s stock are short sold. Based on an average daily volume of 183,100 shares, the days-to-cover ratio is currently 1.2 days.

Femasys Price Performance

Shares of NASDAQ FEMY remained flat at $1.05 during midday trading on Tuesday. The stock had a trading volume of 59,187 shares, compared to its average volume of 73,861. The business’s fifty day moving average is $1.09 and its 200 day moving average is $1.12. The company has a debt-to-equity ratio of 0.86, a quick ratio of 3.26 and a current ratio of 3.94. The stock has a market cap of $24.04 million, a price-to-earnings ratio of -1.30 and a beta of -2.82. Femasys has a fifty-two week low of $0.73 and a fifty-two week high of $2.40.

Femasys (NASDAQ:FEMY) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%. The company had revenue of $0.55 million during the quarter, compared to analyst estimates of $0.40 million. On average, analysts expect that Femasys will post -0.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

FEMY has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Femasys in a report on Tuesday, December 3rd. Chardan Capital lowered their price target on Femasys from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, November 13th.

Hedge Funds Weigh In On Femasys

Several hedge funds have recently made changes to their positions in FEMY. Geode Capital Management LLC boosted its position in shares of Femasys by 9.2% in the 3rd quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock valued at $229,000 after purchasing an additional 17,473 shares during the period. XTX Topco Ltd boosted its stake in Femasys by 123.9% in the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after purchasing an additional 18,004 shares during the period. Finally, Aljian Capital Management LLC purchased a new position in Femasys during the 3rd quarter worth approximately $27,000. Institutional investors and hedge funds own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.